專業(yè)經(jīng)驗(yàn)：

擅長(zhǎng)各種良性惡性血液病的MICM（形態(tài)、免疫分型、染色體、融合基因、基因突變）綜合診斷，并根據(jù)相應(yīng)結(jié)果進(jìn)行危險(xiǎn)度分層分層，給以相應(yīng)個(gè)體化治療。擅長(zhǎng)惡性血液病治療，特別是各型白血病、淋巴瘤、骨髓瘤的化療、靶向治療和免疫治療。在復(fù)發(fā)/難治惡性血液病方面積累大量經(jīng)驗(yàn)，參考國(guó)際最新藥物和免疫療法，為患者制定個(gè)體化治療方案。擅長(zhǎng)急性早幼粒細(xì)胞白血病的治療，無論是初治還是復(fù)發(fā)均有大量成功經(jīng)驗(yàn)并發(fā)表相關(guān)文章。擅長(zhǎng)自體移植治療淋巴瘤、多發(fā)性骨髓瘤。

參與并主持多項(xiàng)藥物臨床試驗(yàn)。2005年開始在應(yīng)用DC-CIK、NK細(xì)胞治療聯(lián)合化療治療中低危急性髓系白血病并發(fā)表相關(guān)文章。2015年開始應(yīng)用CD19 /CD22 CART細(xì)胞治療急性B淋巴細(xì)胞白血病，B細(xì)胞淋巴瘤、BCMA CART治療多發(fā)性骨髓瘤。2021年開始應(yīng)用CD7 CART細(xì)胞治療急性T淋巴細(xì)胞白血病,T細(xì)胞淋巴瘤。在我院率先開展自體移植續(xù)貫雙靶點(diǎn)CART治療伯基特淋巴瘤等高危B細(xì)胞淋巴瘤，并取得很好的治療效果。完成CART治療病例1000例以上，積累大量臨床經(jīng)驗(yàn)，挽救大量患者生命。多次在國(guó)內(nèi)外重要會(huì)議上發(fā)言或發(fā)表墻報(bào)，并在國(guó)外核心期刊上發(fā)表多篇相關(guān)文章。2018至2020年，3次被美國(guó)血液學(xué)年會(huì)（ASH）選做CART治療相關(guān)的口頭報(bào)告，2024年被歐洲血液學(xué)年會(huì)（EHA）選做CART治療相關(guān)的口頭報(bào)告。

另外，對(duì)于HLA在造血干細(xì)胞移植中的作用做了大量較深入的研究。擔(dān)任HLA配型室主任。多次在國(guó)家級(jí)HLA會(huì)議上做相關(guān)發(fā)言，并在國(guó)家級(jí)雜志上發(fā)表數(shù)篇文章。

執(zhí)業(yè)經(jīng)歷：

1999-2003年，日本大阪大學(xué)血液腫瘤內(nèi)科，獲得博士學(xué)位。
2003年-2004年，北京大學(xué)人民醫(yī)院血液病研究所北京臍帶血庫 HLA配型室主任。
2005年-2012年，北京市道培醫(yī)院 血液科住院醫(yī)生。2007年起，血液科主治醫(yī)師，HLA配型室主任。
2012年-2015年，河北燕達(dá)醫(yī)院陸道培血液中心，血液科及免疫治療副科主任醫(yī)師、HLA配型室主任。

2015年-今，河北燕達(dá)陸道培醫(yī)院，普通血液科主任醫(yī)師、HLA配型室主任。

社會(huì)職稱：

主任醫(yī)師，血液學(xué)博士。中國(guó)抗癌協(xié)會(huì)第五屆血液腫瘤專業(yè)委員會(huì)造血干細(xì)胞移植與細(xì)胞治療學(xué)組委員、中國(guó)醫(yī)師協(xié)會(huì)血液科醫(yī)師分會(huì)委員、中國(guó)研究型醫(yī)院學(xué)會(huì)細(xì)胞研究與治療學(xué)專業(yè)委員會(huì)委員、中國(guó)輸血協(xié)會(huì)人類組織抗原專業(yè)會(huì)專家組委員、北京市抗癌協(xié)會(huì)血液淋巴血液腫瘤專業(yè)委員會(huì)委員、北京市癌癥防治學(xué)會(huì)紅細(xì)胞疾病專業(yè)委員會(huì)委員、河北省血液學(xué)會(huì)淋巴瘤專業(yè)委員會(huì)委員，廊坊市門診特殊疾病鑒定專家、廊坊市抗癌協(xié)會(huì)藥物臨床試驗(yàn)安全性評(píng)價(jià)專業(yè)委員會(huì)常務(wù)委員。

第一作者論文

1. Zhang X, Yang J, Li J, et al. Analysis of 60 patients with relapsed or refractory T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma treated with CD7-targeted chimeric antigen receptor-T cell therapy. Am J Hematol. 2023 Dec;98(12):1898-1908. doi: 10.1002/ajh.27094.

2. Zhang X, Wang T, Zhang Y, et al. Characteristics and therapeutic approaches for patients diagnosed with T-ALL/LBL exhibiting t(8;14)(q24;q11)/TCRA/D:MYC translocation. Leuk Lymphoma. 2023 Sep 7:1-7. doi: 10.1080/10428194.2023.2254428.

3. Zhang X, Wu S, Yang J, et al. Long-term retrospective study of retinoic acid combined with arsenic and chemotherapy for acute promyelocytic leukemia. Int J Hematol. 2023 Apr;117(4):530-537. doi: 10.1007/s12185-022-03507-5.

4. Gailing zhang, Xian zhang.急性髓系白血病化療術(shù)后并發(fā)肌肉毛霉感染1例，中國(guó)真菌學(xué)雜志 2021，16（6）：403-406

5. Zhang X, Yang J, Li J, et al. Factors associated with treatment response to CD19 CAR-T therapy among a large cohort of B cell acute lymphoblastic leukemia. Cancer Immunol Immunother. 2021 Aug 7. doi: 10.1007/s00262-021-03009-z.

6. Xian Zhang, Xin-an Lu, Junfang Yang, et al. Efficacy and safety of anti-CD19 CAR T-cell therapy in 110 patients with B-cell acute lymphoblastic leukemia with high-risk features. Blood dvances.2020,4(10): 2325-2338.

7. Chen YH, Zhang X, Cheng YF, et al. Long-term follow-up of CD19 chimeric antigen receptor T-cell therapy for relapsed/refractory acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation. Cytotherapy. 2020 Dec;22(12):755-761. doi: 10.1016/j.jcyt.2020.08.002.

8. Xian Zhang, Jing-Jing Li, Pei-Hua Lu. Advances in the development of chimeric antigen receptor-T-cell therapy in B-cell acute lymphoblastic leukemia. Chinese Medical Journal.2020;133(4):474–482.

9. Xian Zhang, Junfang Yang, Lisong Song, et al.5 Years of Clinical DC-CIK/NK Cells Immunotherapy for Acute Myeloid Leukemia - A Summary. Immunotherapy.2020; 12(1):63-74.

10. 張弦，張改玲，蘇云超等。西達(dá)本胺聯(lián)合化療治療復(fù)發(fā)難治性急性白血病患者38例。 [J].中國(guó)新藥與臨床雜志,2019年6月，38卷，6期。

11. 張弦，伍平，王卉等。急性紅白血病4例病例討論及文獻(xiàn)復(fù)習(xí)。 [J].診斷學(xué)理論與實(shí)踐,2018,17(6):718-722

12. 張弦 張艷玲 王建玲等，HLA-A/B/C/DRB1/DQB1對(duì)于非血緣移植的影響分析。中國(guó)實(shí)驗(yàn)血液學(xué)2011年19（1）

13. 張弦 張艷玲 王建玲等。HLA氨基酸三維構(gòu)象在非血緣移植中的作用分析。中國(guó)實(shí)驗(yàn)血液學(xué)2011年19（2）

14. 張弦 張艷玲 王建玲等。抑制性和激活性KIR在親緣半相同造血干細(xì)胞移植中的作用。中華血液學(xué)雜志 2011年8月第32卷第8期]

15. Zhangxian. The Role of HLA Antibodies in HLA Mismatched Allogeneic Hematopoietic Stem Cell Transplantation. CLINICAL TRANSPLANTS 2014 CHAPTER 31 p.245-250.

16. 張弦 劉開彥 陸道培。自然殺傷細(xì)胞免疫球蛋白樣受體在臍帶血移植治療白血病中的作用。中華醫(yī)學(xué)雜志2006年第86卷第42期 2962-2965頁

17. Xian Zhang, Takashi Machii, Yuzuru Kanakura，et, al. Constitutively activated Rho GTPases regulate the growth and morphology of hairy cell leukemia (HCL) cells. International Journal of Hematology 2003 Apr;77(3):263-73.

國(guó)內(nèi)外重要會(huì)議發(fā)表

1. Immune reconstitution after CD7 CAR-T cell therapy for refractory /relapsed acute T-lymphoblastic leukemia/lymphoblastic lymphoma(R/R T-ALL/LBL). EHA MEETING 2024. Oral.

2. High Efficacy and Safety of Nanobody Based Anti-BCMA CAR-T cell Therapy in Treating Patients with Relapsed or Refractory Multiple Myeloma. ASH MEETING 2023. Poster.

3. Features and treatment of patients with t(8;14)(q24;q11) / TCRA/D::MYC translocated T acute lymphoblastic leukemia/lymphoma (T-ALL/LBL). EHA MEETING 2023. Poster.

4. The Efficacy of Chidamide Maintenance Therapy after CAR-T Therapy for Refractory or Relapsed B-Cell Acute Lymphoblastic Leukemia. ASH MEETING 2022. Poster.

5. Evolution and Proliferation of CD7 CAR-T Cells Compared to CD19 CAR-T Cells Therapies for Acute Leukemia. ASH MEETING 2021. Poster.

6. Factors Associated with Outcomes Among Refractory/Relapsed TP53-Mutated/Chromosome 17p Deletion Acute B-Cell Lymphoblastic Leukemia (B-ALL) Patients Treated with CD19-Targeted Chimeric Antigen Receptor (CAR)-T Therapy. ASH MEETING 2021. Poster.

7. First-In-Human Clinical Study of A Novel CD7-Targeted Chimeric Antigen Receptor (CAR)-T Cell Therapy for Refractory/Relapsed Mixed Phenotype Acute Leukemia (MPAL).ASH MEETING 2021. Poster.

8. Factors Predicting Long-Term Survival Following CD19 CAR T-Cell Therapy in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia. ASH MEETING 2020. Poster.

9. Feasibility, and Efficacy of Donor-Derived CD19-Targeted CAR T-Cell Therapy in Refractory/Relapsed(R/R) B-cell acute lymphoblastic leukemia (B-ALL) Patients. ASH MEETING 2020. Oral presentation.

10. CART治療道培經(jīng)驗(yàn)分享. 中國(guó)疾病細(xì)胞/生物治療大會(huì) 2019.12。講課

11. Analysis of Factors Predicting Treatment Response of 254 Patients Who Received CD19-targeted CAR-T Cell Therapy for Relapsed/Refractory (R/R) B-cell Acute Lymphoblastic Leukemia (B-ALL).ASH MEETING 2019.  Oral presentation December 7, 2019,

12. The Safety and Efficacy of CAR-T Therapy for R/R B ALL. 2nd Annual Summit on Hematologic Malignancies-Asia, Tokyo. Apr 25,2019.

13. fficacy and Safety of CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy for B-Cell Acute Lymphocytic Leukemia (B-cell ALL) in a Large Cohort Including Patients with Extramedullary Disease(EMD), High Leukemia Burden, BCR-ABL (+) Mutation,TP53 Mutation, and Post-Transplant Relapse. ASH MEETING 2018. Oral presentation  

14. A Long-Term Retrospective Analysis of Arsenic-Containing Triple-Agents Treatment for Acute Promyelocytic Leukemia (APL) in a Cohort from a Single Hospital. ASH MEETING 2018. POSTER   

15. CAR-T Treatment of R/R B-ALL Cell Therapy World Asia 2018.9.20 Oral.

16. 單中心含砷三聯(lián)藥物治療急性早幼粒細(xì)胞白血病17年回顧性分析.中華醫(yī)學(xué)會(huì)血液學(xué)年會(huì) 墻報(bào) 2018.10.25

17. A 11-year Clinical Summary of DC - CIK / NK Cell Immunotherapy for 152 Patients with Acute Myeloid Leukemia.中華醫(yī)學(xué)會(huì)血液學(xué)年會(huì) 墻報(bào) 2018.10.25

18. A 11-year Clinical Summary of DC - CIK / NK Cell Immunotherapy for 152 Patients with Acute Myeloid Leukemia. ASH MEETING 2018.Poster

19.  北醫(yī)繼續(xù)教育 DC-CIK/NK細(xì)胞免疫治療白血病 2016.11.7 北京大學(xué)醫(yī)學(xué)部。講課

20. 2016 7.8 中國(guó)輸血協(xié)會(huì)HLA學(xué)術(shù)委員會(huì)學(xué)會(huì)   沈陽HLA  ASHI 新進(jìn)展。講課